^131I治疗Graves甲亢合并肝功能损害或血细胞减少的优势与风险  

The advantage and risk of ^131I treatment in hyperthyroidism combined with liver injury or blood cell reduction

作　　者：张丽花[1] 蒋宁一[1] 

机构地区：[1]中山大学孙逸仙纪念医院核医学科,广州510120

出　　处：《国际放射医学核医学杂志》2015年第6期483-486,492,共5页International Journal of Radiation Medicine and Nuclear Medicine

基　　金：基金项目：公益性卫生行业科研专项（200802028）

摘　　要：目前甲状腺功能亢进症（甲亢）治疗主要有3种方法：抗甲状腺药物治疗、mI治疗和手术治疗。随着”。I在甲亢治疗中的安全性得到肯定，临床上选择wI治疗的病例不断增加，特别是甲亢伴合并症时选择“I治疗较多且备受关注。笔者结合国内外最新相关报道及临床实践，就”’I治疗甲亢合并肝功能损害或血细胞减少两种合并症的优势与风险作简要综述。At present, anti-thyroid drugs, radioactive iodine ^131I） and surgical therapy were considered as the three major methods for hyperthyroidism therapy. With the acceptance of the safety of ^131I therapy in hyperthyroidism, more and more patients become to choose it as their therapeutic method, especially the patients with liver injury or blood cell reduction complications. This paper summaries the advantages and risks of ^131I therapy in this two special hyperthyroidism patients groups according to the recent paper and clinical practice.

关 键 词：格雷夫斯病 甲状腺功能亢进症 近距离放射疗法 肝损伤 血细胞减少 

分 类 号：R581.1[医药卫生—内分泌]